ReviewGynecologic oncology research and practice2017
Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.
Review in Gynecologic oncology research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06084195 (Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging), which is not on this map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.Gynecologic oncology · 2021Pooled it
- Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.Nature communications · 2023Trial
- Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.The Journal of clinical investigation · 2026Review
- Association of homologous recombination repair gene mutation with clinical prognosis in histological subtypes of epithelial ovarian cancer patients.Journal of gynecologic oncology · 2026Article
- Comparison of MR Imaging of High-grade Serous Carcinomas with and without Homologous Recombination-deficiency.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- Whole genome sequencing approach to assess homologous recombination deficiency in a pan-cancer cohort.Communications medicine · 2026Article
- Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD?International journal of women's health · 2026Review
- Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Artificial intelligence in ovarian cancer: advancing in precision diagnosis and clinical management.Frontiers in immunology · 2026Review
- Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.The Journal of clinical investigation · 2025Article
- PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies.Biomedicines · 2025Review
- Dual targeting of Aurora Kinase A and poly (ADP-ribose) polymerase as a therapeutic option for patients with ovarian cancer: preclinical evaluations.Journal of cancer research and clinical oncology · 2025Article
- Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023).Future oncology (London, England) · 2025Article
- Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids.Scientific reports · 2024Article
- The Multiple Functions of HB-EGF in Female Reproduction and Related Cancer: Molecular Mechanisms and Targeting Strategies.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- AcornHRD: an HRD algorithm highly associated with anthracycline-based neoadjuvant chemotherapy in breast cancer in China.European journal of medical research · 2024Article
- In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study.Journal of clinical pathology · 2024Article
- Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.Cancers · 2024Review
- PARP Inhibitors in Breast Cancer: a Short Communication.Current oncology reports · 2024Review
- Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2024Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Until recently our knowledge of a genetic contribution to ovarian cancer focused almost exclusively on mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.